Navigation Links
ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Date:3/6/2008

- Update on Clinical Developments

MONTREAL, March 6 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announces favorable top-line findings from the third cohort in its Phase II trial with PBI-1402 in patients with chemotherapy-induced anemia ("CIA"). Analysis of the compiled data from a total of 18 patients showed an overall statistically significant increase of the mean hematocrit values at weeks 4, 6 and 8, and of the hemoglobin values at week 8. At week 8, p values were 0.02 for hematocrit and hemoglobin. More detailed results from the study have been submitted to the European Hematology Association for presentation at their June 2008 meeting in Copenhagen.

"These results are very encouraging and continue to demonstrate the efficacy and safety profile of PBI-1402, a non-EPO (erythropoietin) treatment for CIA," states Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. "We are excited about the prospects for PBI-1402 for the treatment of anemia in oncology since, unlike EPO, PBI-1402 demonstrated some anticancer activity in animal models. We look forward to sharing more detailed clinical trial results."

Other PBI-1402 development highlights include the extension of the enrollment for the PBI-1402 CIA trial to include an additional 12 patients receiving the lowest trial dose. Data from these additional patients are expected by June 2008.

In addition, a new Phase II study in patients with anemia resulting from chronic kidney disease has been scheduled. This multi-center study will be placebo controlled and will examine the effect of PBI-1402 on anemia, as well as several other clinical parameters. Conclusive results obtained recently in animal models have confirmed the erythropoiesis activity of PBI-1402 even when there is little or no endogenous EPO produced by the kidney.

About PBI-1402

PBI-1402 is an orally active compound being develo
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
2. ProMetic provides business update - Over $35 million worth of business secured in January
3. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
4. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
5. VaxGen Reports Financial Update
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
8. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
9. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has priced an underwritten registered offering of 3,900,000 ... $9.00 per share, and granted the underwriters in the ... additional 585,000 shares of its common stock. The gross ... is expected to close on May 6, 2015, subject ...
(Date:5/1/2015)... -- Investor-Edge has initiated coverage on ... GENE ), Agilent Technologies Inc. (NYSE: A ... ), Sequenom Inc. (NASDAQ: SQNM ), and ... report on Genetic Technologies can be accessed at ... the NASDAQ Composite ended at 4,941.42, down 1.64%, ...
(Date:4/30/2015)... South Carolina (PRWEB) May 01, 2015 ... system services, is extremely proud to announce that for ... been named as a winner of a Queen’s Award ... success for the design and manufacture of a unique ... is the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that it has commenced an underwritten public ... to grant the underwriters a 30-day option to purchase ... of common stock offered in the public offering. The ... be no assurance as to whether or when the ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... International,Corporation (Nasdaq: PRXL ) announced today that ... be presenting at the Thomas,Weisel Partners Healthcare Conference ... September 7th at 8:35 a.m. ET. A live ... "Investor Relations Webcasts",section of PAREXEL,s web site at ...
... 5 Hyperion,Therapeutics, a biopharmaceutical company focused on ... for the,treatment of Urea Cycle Disorders (UCD) and ... B financing. Leading the round was,Sofinnova Ventures, with ... of Menlo Park, CA. WRF Capital of Seattle, ...
... Cryopreservation Expert, BOTHELL, Wash., Sept. 5 ... developer and marketer of,proprietary hypothermic storage and cryopreservation ... the expansion of its Scientific,Advisory Board (SAB) with ... quality and regulatory assurance and in cryopreservation of ...
Cached Biology Technology:PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference 2Hyperion Therapeutics Secures $40 Million In Series B Round 2BioLife Solutions Expands Scientific Advisory Board 2BioLife Solutions Expands Scientific Advisory Board 3BioLife Solutions Expands Scientific Advisory Board 4
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... March 23, 2015 SoundView Technology Group issues a ... NXTD ) Wocket smart wallet. SoundView was one of the ... their experience with the Wocket in multiple scenarios and outlets. ... Foods and other retailers, making both debit and credit card ... also says, "If the company meets their plans in 2015, ...
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... unused agricultural land could produce enough biomass to meet ... the environment, according to research led by Professor Gail ... funded by the UK Energy Research Centre (UKERC), is ... at the potential of planting short rotation coppice (poplar ...
... will not only teach us more about the way neurons ... diagnostics and therapies for neurological diseases such as Parkinson,s," says ... take a major toll on society. More than 8% of ... cent suffers from a mental disturbance and the number of ...
... Avila Therapeutics, Inc., a biotechnology company developing novel ... a scientific review article in Nature Reviews Drug ... www.nature.com/reviews/drugdisc , Vol. 10, April 2011, Singh, J.). ... and how structural bioinformatics coupled with structure-based drug design ...
Cached Biology News:Short rotation energy crops could help meet UK's renewable energy targets 2Skywalker ensures optimal communication between neurons 2New opportunities for covalent drugs published by Avila scientists 2
... excluding l-[U-14C]methionine, 1.85 MBq, 50 uCi. ... > 1.85 GBq/mg atom carbon, ... Mixture of Ala, Arg, Asp, Glu, ... Pro, Ser, Thr, Tyr and Val.1.85 ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Request Info...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
Biology Products: